Series A

Phylagen traces corporates for $14m series A
The environmental microbiome testing kit maker, based on Oregon research, has collected series A capital from investors including Western Digital Capital and 3M Ventures.
Glycotest captures $3m from Fosun Pharma
The liver disease diagnostics spinout has secured the first tranche of a $10m series A investment by Fosun Pharma initially announced in October 2018.
Passage Bio follows $116m series A trajectory
Passage Bio will develop therapies for diseases affecting the central nervous system based on research by James Wilson at Penn, after raising almost $116m in a series A round.
Vor roars to $42m series A
Osage University Partners has contributed to a series A round for Vor Biopharma, an oncology drug developer based on work by Siddhartha Mukherjee at Columbia University.
Recida rolls out from Frazier Healthcare
Venture capital firm Frazier Healthcare Partners has spun out a US-based antibiotics developer with the help of grant funding from a Boston University-operated body and a $8.5m series A round.
Torigen vaccinates $3.1m series A
Building on research by a former University of Minnesota professor, Torigen Pharmaceuticals has begun in-veterinary testing of its immunooncology vaccine for companion animals.
Sustainable Bioproducts sucks in $33m
Danone Manifesto Ventures and ADM Ventures both took part in a series A round for the Montana State University-backed Nasa spinout, which is developing edible proteins.
Sousei hosts Kyoto University for $4.1m
Smart home technology manufacturer Sousei Technology also collected funding from Aioi Nissay Dowa Insurance in a round that will help it deliver upgrades and additional services.

Other News

Stanford gets in Sandbox for $68m round
Virtual reality entertainment operator Sandbox VR has amassed $68m in series A capital from investors including Stanford University.
Liquid Instruments signals for $8.2m
Australian National University helped supply series A funding to scientific testing device manufacturer Liquid Instruments, which is led by a professor from the university’s College of Science.
Wren Therapeutics settles on $23.3m series A
Wren Therapeutics is commercialising Cambridge and Lund research into therapies for protein misfolding diseases, which include Alzheimer's and motor neurone disease.
Vast Therapeutics inhales $15m
The respiratory disease drug developer has collected series A funding from investors including Shionogi to fund clinical trials of its lead drug candidate .
Boston Metal strikes $20m
MIT molten metal production spinout Boston Metal has drawn funding from the Engine in its first publicly disclosed funding round.
Apic Bio picks up $40m
The series A funding will help UMass-founded genetic disease therapy developer Apic Bio progress targeted drugs for ALS and Alpha-1 antitrypsin deficiency.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
Sphere Fluidics circles $2.5m
test reg